================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) FEBRUARY 10, 2005
MOLECULAR DEVICES CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 0-27316 94-2914362
- ---------------------------- ---------------- -------------------
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
1311 Orleans Drive, Sunnyvale, CA 94089
---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (408) 747-1700
------------------------------------------------------------
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On February 10, 2005, Molecular Devices Corporation ("Molecular
Devices") reported its financial results for the quarter ended
December 31, 2004. A copy of the press release issued by
Molecular Devices on February 10, 2005 concerning the foregoing
results is furnished herewith as Exhibit 99.1 and is incorporated
herein by reference.
The information in this report, including the exhibit hereto,
shall not be deemed to be "filed" for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that Section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. The
information contained herein and in the accompanying exhibit
shall not be incorporated by reference into any filing with the
U.S. Securities and Exchange Commission made by Molecular
Devices, whether made before or after the date hereof, regardless
of any general incorporation language in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
99.1 Press release, dated February 10, 2005, entitled
"Molecular Devices Reports Record Revenues and
Earnings for Fourth Quarter of 2004," issued by
Molecular Devices.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MOLECULAR DEVICES CORPORATION
Date: February 10, 2005 By: /s/ Timothy A. Harkness
-----------------------------------
Timothy A. Harkness
Senior Vice President and
Chief Financial Officer
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
- ----------- --------------------------------------------------------------
99.1 Press release, dated February 10, 2005, entitled "Molecular
Devices Reports Record Revenues and Earnings for Fourth
Quarter of 2004," issued by Molecular Devices.